select trial semaglutide Weight loss in the STEP trials with semaglutide. Data represent the

❤️ Heart protection that works even without diabetes. The SELECT trial proved semaglutide 2.4 mg cut major cardiovascular events by 20% in people who had heart disease + overweight/obesity but no diabetes

20.10

★★★★☆4.8 (126)

The SELECT trial. Semaglutide 2.4mg. The headline: "20% reduction in major cardiovascular events." Here is what 20% actually means. The placebo group had an 8% event rate. The semaglutide group had a

26.37

★★★★★4.9 (98)

Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial

28.62

★★★★★5.0 (157)

Efficacy of Oral Semaglutide: Overview of the PIONEER Clinical Trial Program and Implications for Managed Care

29.79

★★★★★4.7 (84)

Ozempic was dismissed as the “lazy” weight-loss drug. Then researchers analyzed over 2 million people and the results changed the conversation completely. A 2025 study published in Nature Medicine found GLP-1 drugs

23.85

★★★★★4.9 (203)

Ongoing #GLP1 -RA Trials on #ASCVD #SELECT: Semaglutide vs Placebo in Patients With Obesity and ASCVD Without DM #SOUL: Semaglutide vs Placebo in Adults With T2D With ASCVD or CKD #SURPASS-CVOT: Tirzepatide

24.88

★★★★★5.0 (176)

SELECT Trial

29.94

★★★★★4.8 (132)